<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250514065735N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-05-29</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of acupuncture intervention with pharmacological treatment in improving neck pain and stiffness in patients with cervical spondylosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of acupuncture intervention with pharmacological treatment in improving neck pain and stiffness in patients with cervical spondylosis - clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83568</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization in this study will use a permuted block design with a block size of 4. In this method:

"A" represents a participant receiving the intervention (acupuncture).

"B" represents a participant in the control group (pharmacotherapy).

Implementation:
All possible 4-sequence permutations (total of 6 combinations) will be used:

ABAB

BABA

AABB

BBAA

ABBA

BAAB

Blocks of 4 will be randomly selected to ensure balanced group allocation.</study_design>
      <phase>2</phase>
      <hc_freetext>Cervical spondylosis without myelopathy or radiculopathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Pharmacological Treatment Protocol: Piroxicam (NSAID):Dosage: 10 mg oral capsule Frequency: 1 capsule twice daily (BID)Duration: 10 days Methocarbamol (Muscle Relaxant):Dosage: 500 mg oral tablet Frequency: 3 tablets (1500 mg) three times daily (TID)Duration: 10 days. Intervention 2: Intervention group: Acupuncture Points for Cervical Spondylosis: Standard Points:SI-3 (Houxi)BL-10 (Tianzhu)BL-11 (Dazhu)BL-14 (Jueyinshu)BL-21 (Weishu)BL-60 (Kunlun)LI-4 (Hegu) – For lateral neck painLI-17 (Tianding) – For central/posterior painDU-14 (Dazhui)DU-20 (Baihui)SJ-5 (Waiguan)GB-20 (Fengchi)GB-21 (Jianjing)GB-34 (Yanglingquan)GB-39 (Xuanzhong)Clinical Rationale: Local Points (e.g., GB-20, BL-10): Target neck stiffness/pain directly. Distal Points (e.g., LI-4, GB-34): Enhance systemic analgesia and Qi flow.DU/GV Points (e.g., DU-14): Regulate Governor Vessel for spinal support.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No further information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Davoud Gholami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 366, Street 8, Nastran 2 Ave, Goldasht maali abad</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7188667917</zip>
        <telephone>+98 71 3639 1775</telephone>
        <email>d_gholamid@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Davoud Gholami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 366, Street 8, Nastran 2 Ave, Goldasht maali abad</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7188667917</zip>
        <telephone>+98 71 3639 1775</telephone>
        <email>d_gholamid@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Signs of Neck Pain and Stiffness Lasting More Than 6 Months</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Clinical signs of effusion, inflammation, redness
Rheumatoid arthritis, Inflammatory arthropathy, Fibromyalgia
Collagen vascular disease (Lupus), Gout,  Cervical disc pathology
Trauma, Fracture, Cervical spine surgery
History of allergy and Allergic reaction to medications used (NSAIDs and Methocarbamol)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M47.812</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cervical spondylosis without myelopathy or radiculopathy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Pharmacological Treatment Protocol: Piroxicam (NSAID):Dosage: 10 mg oral capsule Frequency: 1 capsule twice daily (BID)Duration: 10 days Methocarbamol (Muscle Relaxant):Dosage: 500 mg oral tablet Frequency: 3 tablets (1500 mg) three times daily (TID)Duration: 10 days</i_keyword>
      <i_keyword>Intervention group: Acupuncture Points for Cervical Spondylosis: Standard Points:SI-3 (Houxi)BL-10 (Tianzhu)BL-11 (Dazhu)BL-14 (Jueyinshu)BL-21 (Weishu)BL-60 (Kunlun)LI-4 (Hegu) – For lateral neck painLI-17 (Tianding) – For central/posterior painDU-14 (Dazhui)DU-20 (Baihui)SJ-5 (Waiguan)GB-20 (Fengchi)GB-21 (Jianjing)GB-34 (Yanglingquan)GB-39 (Xuanzhong)Clinical Rationale: Local Points (e.g., GB-20, BL-10): Target neck stiffness/pain directly. Distal Points (e.g., LI-4, GB-34): Enhance systemic analgesia and Qi flow.DU/GV Points (e.g., DU-14): Regulate Governor Vessel for spinal support.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>VAS (Visual Analog Scale) Assessment Protocol: Pain intensity will be evaluated using the Visual Analog Scale (VAS) at the following time points: Baseline (upon study entry)Post-intervention follow-ups: Week 2 Week 6 Week 12. Timepoint: Baseline (upon study entry)Post-intervention follow-ups: Week 2 Week 6 Week 12. Method of measurement: VAS (Visual Analog Scale) Assessment Protocol.</prim_outcome>
      <prim_outcome>NDI (Neck Disability Index) Assessment Protocol: The Neck Disability Index (NDI) questionnaire will be used to evaluate the severity of pain-related disability at the following intervals: Baseline (pre-intervention)Post-treatment follow-ups: Week 2Week 6Week 12. Timepoint: Baseline (pre-intervention)Post-treatment follow-ups: Week 2Week 6Week 12. Method of measurement: NDI (Neck Disability Index) Assessment Protocol.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cervical Spine Range of Motion (ROM) Assessment Protocol Measurement Method: Cervical ROM will be quantitatively evaluated using a goniometer at the following time points: Baseline (pre-intervention)Post-intervention follow-ups: Week 2Week 6Week 12. Timepoint: Baseline (pre-intervention)Post-intervention follow-ups: Week 2Week 6Week 12. Method of measurement: goniometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-02-01</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Ethics Committee, Office of Research Affairs 3rd Floor, Building No. 3 School of Medicine, Shiraz University of Medical Sciences Imam Hossein Square, Zand Street Shiraz, Iran Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
